Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 The UPMC Center for ... Fellows in the Emerging Leaders in Biosecurity Initiative (ELBI). ... in the field of biosecurity, UPMC has selected 28 ... wide array of backgrounds, including biological science, medicine, policy, ... "With the vision and support of the ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... N.J., June 18 HemoCue(R) AB, a,global point-of-care ... Diagnostics Incorporated (NYSE: DGX ), today announced,that ... quantitative point-of-care,test for screening for, diagnosing and monitoring ... U.S. Food and Drug Administration (FDA). With,the FDA ...
... industry information on ... ... the world,s leading,online community for the bioscience industry, launched today ... industries in Europe. EuroBio(TM) features dynamic informational,Hotbed Web pages for ...
... SALT LAKE CITY, June 18 ARUP Laboratories, ... a leader in,innovative laboratory research and development, announced ... with Pathology Service Associates, LLC,(PSA), a nationwide network ... support to independent pathologist practices. The,agreement, effective June ...
Cached Biology Technology:HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5BioSpace Launches EuroBio(TM) Online Community 2ARUP Laboratories Partners With Pathology Service Associates 2ARUP Laboratories Partners With Pathology Service Associates 3
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... This press release is available in French . ... University of Montreal,s Department of Chemistry have discovered that traces ... our water by sewers. " E coli bacteria is ... pollution of our water from storm water discharge, but because ...
... by 2050, according to a new projection by David ... Minnesota,s College of Biological Sciences, and colleagues, including Jason ... and Natural Resource Sciences. Producing that amount of ... nitrogen in the environment and cause the extinction of ...
... WEST LAFAYETTE, Ind. ╨ Future astronauts spending Thanksgiving in ... most traditional parts of the day,s feast: fresh sweet ... horticulture, and Gioia Massa, a former postdoctoral researcher at ... the required growing space while not decreasing the amount ...
Cached Biology News:Chemistry professor links feces and caffeine 2New projection shows global food demand doubling by 2050 2Thanksgiving in space may one day come with all the trimmings 2
... delivery of siRNA while maintaining high cell ... 96 samples simultaneously , Fast: ... to post-electroporation incubation , Highly ... Designed for use with the Bio-Rad Gene ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: